Oropharyngeal Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Oropharyngeal Cancer - Pipeline Review, H2 2016

Oropharyngeal Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Oropharyngeal Cancer - Pipeline Review, H2 2016
Published Oct 30, 2016
144 pages — Published Oct 30, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer Pipeline Review, H2 2016, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape.

Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oropharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.Oropharyngeal Cancer.

Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related

  
Source:
Document ID
GMDHC8628IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Oropharyngeal Cancer Overview81
Therapeutics Development92
  Pipeline Products for Oropharyngeal Cancer Overview91
  Pipeline Products for Oropharyngeal Cancer Comparative Analysis101
Oropharyngeal Cancer Therapeutics under Development by Companies111
Oropharyngeal Cancer Therapeutics under Investigation by Universities/Institutes121
Oropharyngeal Cancer Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Oropharyngeal Cancer Products under Development by Companies161
Oropharyngeal Cancer Products under Investigation by Universities/Institutes171
Oropharyngeal Cancer Companies Involved in Therapeutics Development1812
  Advaxis, Inc.181
  AstraZeneca Plc191
  Cell Medica Limited201
  Genticel S.A.211
  Immunovaccine Inc221
  ISA Pharmaceuticals B.V.231
  Kolltan Pharmaceuticals, Inc.241
  Merck &Co., Inc.251
  Novartis AG261
  PNP Therapeutics, Inc.271
  Tessa Therapeutics Pte Ltd281
  VLPbio291
Oropharyngeal Cancer Therapeutics Assessment309
  Assessment by Monotherapy Products301
  Assessment by Target312
  Assessment by Mechanism of Action332
  Assessment by Route of Administration352
  Assessment by Molecule Type372
Drug Profiles3999
  alpelisib Drug Profile393
  axalimogene filolisbac Drug Profile4216
  Cellular Immunotherapy for HPV Associated Cancers Drug Profile581
  CMD-004 Drug Profile591
  DPXE-7 Drug Profile601
  ganetespib Drug Profile6113
  gedeptin Drug Profile741
  GTL-001 Drug Profile753
  HNVax Drug Profile781
  ISA-101 Drug Profile793
  KTN-3379 Drug Profile824
  nimotuzumab Drug Profile864
  olaparib Drug Profile909
  pembrolizumab Drug Profile9936
  PGV-001 Drug Profile1351
  TT-12 Drug Profile1361
  Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer Drug Profile1371
Oropharyngeal Cancer Dormant Projects1381
Oropharyngeal Cancer Product Development Milestones1394
  Featured News &Press Releases1391
    Aug 11, 2016: Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage1391
    Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company s Lm Technology Platform1392
    Sep 14, 2015: FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac in HPV-Associated Head and Neck Cancer1411
    Jun 09, 2015: U.S. FDA approves IND application for TT12 HP-VST to begin Phase I trial involving Adoptive T cell therapy on Oropharyngeal Cancer and Cervical Cancer1421
Appendix1432
  Methodology1431
  Coverage1431
  Secondary Research1431
  Primary Research1431
  Expert Panel Validation1431
  Contact Us1431
  Disclaimer1441

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Oropharyngeal Cancer - Pipeline Review, H2 2016" Oct 30, 2016. Alacra Store. May 04, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Oropharyngeal-Cancer-Pipeline-Review-H2-2016-2088-16757>
  
APA:
Global Markets Direct - Market Research. (2016). Oropharyngeal Cancer - Pipeline Review, H2 2016 Oct 30, 2016. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Oropharyngeal-Cancer-Pipeline-Review-H2-2016-2088-16757>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.